Use of sugarcane-derived extracts for treating or preventing microbial infections and dysbiosis

JP2023550768A5Pending Publication Date: 2024-11-26POLY GAIN PTE LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023530947
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-23
Filing Date
2021-11-23
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

There is a need for safe and effective treatments and preventive measures against viral infections, particularly those caused by coronaviruses, as well as alternatives to antibiotics for treating microbial infections and modulating microbial communities to reduce greenhouse gas emissions and improve animal health without compromising economic feasibility.

Method used

The use of sugarcane-derived extracts containing polyphenols for inhibiting or inactivating viruses, parasites, protozoa, archaea, fungi, and bacteria, and modulating microbial communities to treat or prevent infections and reduce methane emissions.

Benefits of technology

The sugarcane-derived polyphenols effectively inhibit or inactivate a wide range of pathogens, including coronaviruses, protozoan parasites, and archaea, while modulating microbial communities to enhance animal health and reduce greenhouse gas emissions.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Methods for various therapeutic, preventative, and control measures are disclosed, including administering to a subject an extract containing about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols, and compositions containing about 0.00001% to about 100% by weight of a sugarcane-derived extract. These therapeutic and preventative measures include antibacterial activity, particularly against human respiratory viruses, and treatment of microsporidia infections, such as EHP, in shrimp and prawns. Control measures include reducing methane production in ruminants. Use of these compositions, for example, in dairy cows, improves their health by increasing milk production while minimizing mastitis.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present disclosure relates to the field of inhibiting or inactivating viruses and preventing or treating microbial infections in animals. These extracts are particularly useful against viruses that cause respiratory disease in animals.

[0002] The present disclosure also relates to the use of sugarcane-derived extracts containing polyphenols for inhibiting or inactivating microsporidian parasites and for preventing or treating microsporidian parasite infections in animals. These extracts are particularly useful for Enterocytozoon hepatopenaeis (EHP), a parasitic disease causing disease in aquatic animals such as prawns and shrimp.

[0003] The present disclosure also relates to the use of sugarcane-derived extracts containing polyphenols for inhibiting or inactivating protozoa and preventing or treating protozoal infections in animals, with these extracts being particularly useful against malaria-causing Coccidia and Plasmodium parasites.

[0004] The present disclosure also relates to the use of sugarcane-derived extracts containing polyphenols for inhibiting or inactivating archaea in animals and for preventing or treating archaeal infections. These extracts are particularly useful in the treatment of microbial incompatibility and against methanogens present in ruminants.

[0005] The present disclosure further relates to the use of sugarcane-derived extracts containing polyphenols for preventing or treating mastitis in ruminants, these extracts being particularly useful for preventing or treating mastitis in dairy cows.

[0006] The present disclosure also relates to the use of sugarcane-derived extracts containing polyphenols for inhibiting or inactivating fungi and preventing or treating fungal infections in animals, particularly fungal infections of the Ascomycota and Basidiomycota phyla.

[0007] Mechanistically, the present disclosure relates to the use of sugarcane-derived extracts containing polyphenols to treat, prevent or minimize cytokine storm in animals, as is commonly seen with all pathogen infestations in animals.

[0008] Mechanistically, the present disclosure also relates to the use of a sugarcane-derived extract containing polyphenols to treat, prevent, or minimize at least one of inflammation, tissue, and organ damage resulting from an adaptive immune response in an animal by modulating Toll-like receptors.

[0009] The present disclosure further relates to the use of sugarcane-derived extracts containing polyphenols as adjuvants, either alone or in combination with known adjuvants such as Freund's adjuvant. [Background technology]

[0010] Respiratory disease epidemics have already affected global populations in recent history. Severe Acute Respiratory Syndrome (SARS) emerged in China in 2002, resulting in 8,000 cases with a mortality rate of 10%. Middle East Respiratory Syndrome (MERS) emerged in 2012, resulting in 1,700 cases with a mortality rate of nearly 40%. Coronaviruses have been identified as the infectious agents causing the SARS and MERS epidemics. Combating these viruses presents challenges due to their genetic diversity and ability to jump in and out of humans and new zoonotic hosts.

[0011] In December 2019, an acute respiratory illness broke out in Wuhan, Hubei Province, China, with patients suffering from pneumonia of unknown cause. By January 7, 2020, this new acute respiratory illness was confirmed to be caused by the novel coronavirus SARS-CoV-2. With the help of international travel, cases of this new disease, known as pneumonia caused by a novel coronavirus, spread rapidly throughout China and the world. On March 11, 2020, the World Health Organization declared the disease a pandemic.

[0012] Patients infected with SARS-CoV-2 may be asymptomatic. However, symptomatic patients may experience fever, dry cough, and shortness of breath due to an upper respiratory tract infection. Patients may also experience flu-like symptoms. More severe disease and respiratory distress may occur as the infection progresses and penetrates deeper into the lungs. Secondary infections and extrapulmonary disease (cardiac and renal complications) may also occur. Severe disease is typically characterized by pneumonia-related acute respiratory disease syndrome (ARDS), which is one of the leading causes of death from pneumonia caused by COVID-19.

[0013] There is no definitive treatment for acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2. Instead, supportive care and nonspecific treatment protocols have been used to improve patients' symptoms. In the absence of effective drug therapies, pulmonary ventilation strategies, such as the administration of broad-spectrum antivirals or antibacterial agents or convalescent plasma, alone or in combination, remain the mainstay of available options.

[0014] Furthermore, potential ARDS drug therapies may lack the necessary safety and activity. For example, steroids are known to reduce immune responses and potentially increase viral shedding and should not be used routinely. Attempts to use steroids in the treatment of patients with a history of SARS or MERS outbreaks have been ineffective, as have attempts to use approved antivirals (ribavirin, lopinavir-ritonavir) and immunomodulatory agents. Side effects may be observed when using these medications. For example, anemia has been observed with ribavirin.

[0015] Recently, dexamethasone, a corticosteroid widely used for a variety of illnesses due to its anti-inflammatory and immunosuppressive properties, was tested on hospitalized COVID-19 patients in the UK National Clinical Trial and Rehabilitation and found to be effective in severe cases. Preliminary findings shared with WHO showed that the treatment reduced mortality by about one-third in patients on ventilators and by about one-fifth in patients requiring oxygen only.

[0016] No specific antiviral medications have yet been approved, but remdesivir has been shown to shorten the time to recovery.

[0017] While the development of effective treatments is desirable, it would also be desirable to prevent viral infections, or alternatively, to be able to vaccinate against infectious diseases.

[0018] Prevention of coronavirus infection is typically achieved through physical measures and disinfection. This includes effective handwashing, the use of face masks and shields, gloves, and other forms of personal protective equipment. Simple handwashing with soap, water, or hand sanitizer is effective in inactivating coronaviruses. These measures can prevent individuals from transmitting the virus from their hands to their mouths or nasal passages, where it can then infect the respiratory system. They also prevent transmission through contact with others.

[0019] Once a person is infected with a respiratory coronavirus, wearing a mask can minimize transmission of the virus through the aerosol route. Similarly, wearing a mask in an uninfected individual reduces the likelihood of infection through inhaling virus-containing aerosols.

[0020] However, handwashing products are not suitable for use in the oral and nasal cavities, where infections usually first emerge.

[0021] Therefore, a clear need continues to exist for safe and effective agents to be used not only in hand washes but also in the oral and nasal passages.

[0022] More commonly, viral infections are the cause of severe diseases in humans and animals, and developing appropriate vaccines and effective treatments remains a key priority, especially when potential viruses are highly infectious.

[0023] Some of the virus families that are clinically important to humans and / or animals are: Coronaviridae SARS-CoV-1 SARS-CoV-2 MERS Avian coronaviruses - causing significant economic losses in both broiler and layer chickens. Porcine epidemic diarrhea virus Bovine coronavirus - causes a disease called winter dysentery and can cause severe diarrhea and respiratory infections in calves. Caliciviridae Norovirus - kills 200,000 people each year, has no vaccine or specific treatment, and accounts for approximately 18% of all cases of gastroenteritis. Feline calcium virus - Found in 50% of cats with upper respiratory tract infections. Orthomyxoviridae Influenza A, B, C, and D can all infect humans. Examples of influenza A strains - H1N1 caused the 1918 "Spanish flu" and the 2009 "swine flu." - H2N2 caused the "Asian flu." - H3N2 caused the "Hong Kong flu." - H5N1, "bird" or "avian flu." - - H7N7 has extraordinary zoonotic potential. - H1N2 infects pigs and humans. Salmonella virus - causes anemia and losses in salmon farms. Paramyxoviridae measles Mumps Hendra virus Canine distemper virus - kills many puppies and although a vaccine is available, full protection against the virus does not appear until 16 weeks of age. Newcastle disease virus - a major disease of poultry, for which a vaccine is available, but as eye drops or spray. Pneumoviridae Human metapneumovirus - Common symptoms include runny nose, stuffy nose, sore throat, cough, headache, and fever, which may be thought of as a cold. For people over 72, there is a risk of pneumonia. Flaviviridae West Nile virus Dengue virus - 390 million infections per year Tick-borne encephalitis - no specific treatment available. 10,000-12,000 cases per year Zika virus - no cure, vaccine expected in 2028 Hepatitis C Theiler's disease virus - a common cause of equine hepatitis and liver failure in horses Bovine viral diarrhea virus Classical swine cholera Japanese encephalitis virus – 68,000 cases per year Yellow fever virus Togaviridae Some equine encephalitis viruses

[0024] Animal parasites place a significant burden on animal welfare and contribute to the overall economic costs of agriculture. Parasites are thought to be of three types: protozoa, helminths and arthropods.

[0025] There are many different types of protozoan parasites known to cause disease across both vertebrate and invertebrate species, including, but not limited to, malaria, dysentery, giardia, cryptosporidium, chaga disease, and coccidiosis.

[0026] While some protozoa are specific to one host species, others can infect a range of host species. As a result, the unchecked use of antibiotics, particularly throughout the food supply chain, is increasingly facing restrictions to ensure that these drugs are effective in emergencies.

[0027] Therefore, the need for alternatives to antibiotics to prevent disease progression is an important lever to improve global health and welfare outcomes without compromising economic viability.

[0028] Microsporidia parasites are economically important in aquatic environments, especially in the aquaculture of kuruma prawns and shrimp. Enterocytozoon hepatopenaeis (EHP) is known to infect only the tubular epithelial cells of the hepatopancreas of shrimp. Infection occurs via extrusion of the polar tubules of microsporidia, which then attach to the hepatopancreas of shrimp.

[0029] Among the species that are particularly susceptible to EHP are Penaeus monodon, Vannamei shrimp, and angel shrimp.

[0030] Effective prevention or treatment of infectious diseases such as EHP would be of considerable benefit to the aquaculture industry.

[0031] Beyond their ability to cause disease in a variety of organisms, microbial pathogens are a threat to life on Earth because methanogenic archaea are the largest contributors to agricultural greenhouse gas emissions.

[0032] Methanogens are not associated with disease or parasitism in the animals from which they are isolated. However, the production of gases such as methane during fermentation has been identified as a contributing factor to increased greenhouse gas emissions and global warming. Thus, rather than harming individual animals through disease, methanogens harm the planet through their environmental impacts.

[0033] Ruminants produce the majority of agricultural methane but are also important for the global food and fiber supply, so strategies are needed to mitigate methane emissions while maintaining or increasing production.

[0034] Dietary strategies that modulate an animal's microbiota to inhibit the growth of methanogens while promoting microbial communities that support animal health would meet these goals.

[0035] Ruminants that produce milk are susceptible to mastitis, a bacterial infection that causes inflammation of the udder of dairy cows. This infection is caused by multiple pathogens and is epidemiologically classified as infectious or environmental mastitis. Mastitis is the most prevalent and costly disease of dairy cows worldwide.

[0036] Milk conductivity (EC) has been introduced as an indicator of mastitis over the past decade. EC is determined by the concentration of anions and cations. When a dairy cow has mastitis, the concentration of Na+ and Cl- in the milk increases, leading to an increase in the conductivity of the milk from the infection site. Most automated milking systems incorporate an EC sensor that measures EC during milking.

[0037] An explanation of the utility of conductivity measurement is given in J Dairy Sci. 75 , 606-614 (1992).

[0038] Conductivity measurements of milk from healthy cows are typically between 4.0 and 5.0 millisiemens (mS) at 25°C, while absolute values ​​of conductivity in infected quarters are typically in the range of 5.0 to 9.0 mS. A typical EC profile for cows infected with mastitis shows higher EC levels in the infected quarter for most of the milking period, with peaks at the beginning and end of milking.

[0039] Mild, uncomplicated mastitis in a single quarter is usually treated with intramammary antibiotics such as beta-lactams (amoxicillin, penicillin, cephalosporins). Systemic antibiotics are administered when more than one-quarter of the cow is infected, when udder changes are significant, or when the cow becomes visibly ill. Combination therapy, using both systemic and intramammary antibiotics, is thought to improve bacteriological cure rates and is used in severe cases of mastitis.

[0040] The major economic impacts of mastitis are related to reduced milk production, milk wastage, the cost of medications used for treatment, labor costs associated with treatment, and animal culling. These factors combine to reduce farmers' milk income. It is estimated that Australian dairy farmers lose more than $150 million annually due to poor udder health. Furthermore, the use of antibiotics is now discouraged due to the development of bacterial resistance and the potential for unwanted antibiotic residues in the meat and milk of animals consumed by humans. Summary of the Invention

[0041] In one aspect of the present disclosure, there is provided a composition for inhibiting or inactivating a virus or preventing or treating a viral infection in a subject, comprising about 0.00001% to about 100% by weight of a sugarcane-derived extract, the extract comprising about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols, for use via topical, pulmonary, respiratory, intravenous, or oral routes.

[0042] In another aspect of the present disclosure, there is provided a method for inhibiting or inactivating a virus, or preventing or treating a viral infection in a subject, comprising administering to the subject via topical, pulmonary, airway, intravenous, or oral route an effective amount of a composition comprising about 0.00001% to about 100% by weight of an extract derived from sugarcane, wherein the extract comprises about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols, or about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0043] In another aspect of the present disclosure, there is provided a composition for preventing or treating aquatic animals by inhibiting or inactivating microsporidian parasites, comprising from about 0.00001% to about 100% by weight of a sugarcane-derived extract, the extract comprising from about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or from about 100 CE mg / g to about 500 CE mg / g of polyphenols, wherein the composition is used by including the extract in an aquatic environment.

[0044] In another aspect of the present disclosure, there is provided a method for inhibiting or inactivating microsporidian parasites in an aquatic animal, comprising administering to the animal via its aquatic environment an effective amount of a composition comprising about 0.00001% to about 100% by weight of an extract derived from sugarcane, wherein the extract comprises about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0045] In another aspect of the present disclosure, there is provided a composition for preventing or treating a protozoan infection in an animal by inhibiting or inactivating protozoa, the composition comprising from about 0.00001% to about 100% by weight of a sugarcane-derived extract, the extract comprising from about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or from about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0046] In another aspect of the present disclosure, there is provided a method for inhibiting or inactivating protozoa in an animal, comprising administering to the animal an effective amount of a composition comprising about 0.00001% to about 100% by weight of an extract derived from sugarcane, wherein the extract contains about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0047] In another aspect of the present disclosure, there is provided a composition for preventing or treating archaeal infection in an animal by inhibiting or inactivating archaea, the composition comprising from about 0.00001% by weight to about 100% by weight of a sugarcane-derived extract, the extract comprising from about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or from about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0048] In another aspect of the present disclosure, there is provided a method for inhibiting or inactivating Archaea in an animal, the method comprising administering to the animal an effective amount of a composition comprising about 0.00001% to about 100% by weight of an extract derived from sugarcane, the extract comprising about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0049] In another aspect of the present disclosure, there is provided a composition comprising from about 0.00001% to about 100% by weight of a sugarcane-derived extract for treating microbial incompatibility in an animal by inhibiting or inactivating methanogens, the composition comprising from about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or from about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0050] In another aspect of the present disclosure, there is provided a method of treating microbial incompatibility in an animal, comprising administering to the animal an effective amount of a composition comprising about 0.00001% to about 100% by weight of an extract derived from sugarcane, wherein the extract contains about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0051] In another aspect of the present disclosure, there is provided a composition for preventing or treating a fungal infection in an animal by inhibiting or inactivating fungi, the composition comprising from about 0.00001% to about 100% by weight of an extract derived from sugarcane, the extract comprising from about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or from about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0052] In another aspect of the present disclosure, there is provided a method for inhibiting or inactivating fungi in an animal, comprising administering to the animal an effective amount of a composition comprising about 0.00001% to about 100% by weight of an extract derived from sugarcane, wherein the extract contains about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0053] In another aspect of the present disclosure, there is provided a method for inhibiting or inactivating the life cycle of protozoan parasites in vertebrates and invertebrates or the environments in which they live, comprising administering to the animal an effective amount of a composition comprising from about 0.00001% to about 100% by weight of an extract derived from sugarcane, the extract comprising from about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or from about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0054] In another aspect of the present disclosure, there is provided a composition for inhibiting or inactivating the life cycle of protozoan parasites in vertebrates and invertebrates or the environments in which they live, comprising from about 0.00001% to about 100% by weight of a sugarcane-derived extract, the extract comprising from about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or from about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0055] In another aspect of the present disclosure, there is provided a method for modulating the microbiota in an animal, comprising administering to the animal an effective amount of a composition comprising about 0.00001% to about 100% by weight of an extract derived from sugarcane, wherein the extract contains about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0056] In another aspect of the present disclosure, there is provided a composition for modulating the microbiota of an animal, comprising about 0.00001% to about 100% by weight of an extract derived from sugarcane, wherein the extract contains about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0057] In another aspect of the present disclosure, there is provided a method for mitigating greenhouse gas emissions in an animal by altering the composition of the microbial community associated with the animal, comprising administering to the animal an effective amount of a composition comprising about 0.00001% to about 100% by weight of an extract derived from sugarcane, wherein the extract comprises about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0058] In another aspect of the present disclosure, there is provided a composition comprising about 0.00001% to about 100% by weight of a sugarcane-derived extract for mitigating greenhouse gas emissions in an animal by altering the composition of the animal's associated microbial community, the extract comprising about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0059] In another aspect of the present disclosure, there is provided a method for preventing or treating mastitis in a ruminant, comprising administering to the animal an effective amount of a composition comprising about 0.00001% to about 100% by weight of an extract derived from sugarcane, wherein the extract contains about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0060] In another aspect of the present disclosure, there is provided a composition for preventing or treating mastitis in ruminants, comprising from about 0.00001% to about 100% by weight of a sugarcane-derived extract, the extract comprising from about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols, or from about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0061] In another aspect of the present disclosure, there is provided a method for reducing methane emissions in a ruminant by altering the composition of the microbial community associated with the ruminant, thereby treating or preventing mastitis in the ruminant, comprising administering to the ruminant an effective amount of a composition comprising from about 0.00001% to about 100% by weight of an extract derived from sugarcane, wherein the extract comprises from about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or from about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0062] In another aspect of the present disclosure, there is provided a composition comprising from about 0.00001% to about 100% by weight of a sugarcane-derived extract for treating or preventing mastitis in a ruminant by altering the composition of the animal's associated microbial community, the extract comprising from about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or from about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0063] In another aspect of the present disclosure, there is provided a method for increasing milk production in a ruminant, comprising administering to the ruminant an effective amount of a composition comprising from about 0.00001% to about 100% by weight of an extract derived from sugarcane, wherein the extract contains from about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or from about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0064] In another aspect of the present disclosure, there is provided a composition for increasing milk production in a ruminant, comprising from about 0.00001% to about 100% by weight of an extract derived from sugarcane, the extract comprising from about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or from about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0065] In another aspect of the present disclosure, there is provided a method for reducing methane emissions from ruminants by promoting growth and simultaneously altering the composition of the microbial community associated with the ruminant, the method comprising administering to the ruminant an effective amount of a composition comprising from about 0.00001% to about 100% by weight of a sugarcane-derived extract, the extract comprising from about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or from about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0066] In another aspect of the present disclosure, there is provided a composition comprising from about 0.00001% to about 100% by weight of a sugarcane-derived extract for simultaneously reducing methane emissions from ruminants by altering the composition of microbial communities associated with the ruminants, and promoting ruminant growth, wherein the extract comprises from about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or from about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0067] In another aspect of the present disclosure, there is provided a composition comprising about 0.00001% to about 100% by weight of a sugarcane-derived extract as an adjuvant, alone or in combination with a second adjuvant, wherein the extract contains about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0068] In another aspect of the present disclosure, there is provided a method of improving an immune response to a vaccine, comprising including in a vaccine composition a composition comprising from about 0.00001% to about 100% by weight of an extract derived from sugarcane, wherein the extract comprises from about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or from about 100 CE mg / g to about 500 CE mg / g of polyphenols. [Brief explanation of the drawings]

[0069] FIG. 1 is a bar graph showing the results of Example 3 described herein. FIG. 2 is a bar graph showing the results of Example 5 described herein. FIG. 3 is a bar graph showing the results of Example 6 described herein. FIG. 4 is a bar graph showing the results of Example 7 described herein. FIG. 5 is a bar graph showing the results of Example 8 described herein. FIG. 6 is a bar graph showing the results of Example 14 described herein. FIG. 7 is a bar graph showing the results of Example 13 described herein. FIG. 8 is a graph showing the results achieved in Example 19 for the 0.5% composition. FIG. 9 is a graph showing the results achieved in Example 19 for the 0.5% composition. FIG. 10 is a bar graph showing the results of Example 20 described herein. DETAILED DESCRIPTION OF THE INVENTION

[0070] Unless stated otherwise, any embodiment herein is considered to apply to any other embodiment.

[0071] The scope of the present disclosure is not limited to the specific embodiments described herein, solely for purposes of illustration, and functionally equivalent products, compositions, and methods as described herein are clearly within the scope of the present disclosure.

[0072] In this specification, unless otherwise stated or the context requires otherwise, a reference to a single step, composition of matter, set of steps or set of compositions of matter includes one or more of that step, composition of matter, set of steps or set of compositions of matter.

[0073] Unless otherwise defined, all technical and scientific terms used herein are deemed to have the same meaning as commonly understood by one of ordinary skill in the art (e.g., chemistry, biochemistry, cell culture, molecular biology, pharmacology). Also, unless the context requires otherwise, singular terms shall include complex numbers, and complex numbers shall include the singular. Thus, as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, the term "object" means "one or more objects" unless the context clearly dictates otherwise.

[0074] As used herein, "administering" should be interpreted broadly and includes administering an extract described herein or a composition comprising an extract described herein to a subject, as well as providing an extract described herein or a composition comprising an extract described herein to a cell.

[0075] As used herein, the phrase "effective amount" refers to an amount sufficient to elicit the biological or medical response in a tissue, system, animal, or human that a researcher, veterinarian, physician, or other clinician is seeking. Undesirable effects, such as side effects, may occur along with undesirable effects. Therefore, a practitioner must balance potential benefits and potential risks when determining what constitutes an appropriate "effective amount." The exact amount required will vary from subject to subject, depending on the subject's species, age, general condition, method of administration, and the like. Therefore, it may not be possible to specifically define an exact "effective amount." However, an appropriate "effective amount" for any individual case can be determined by one of ordinary skill in the art using routine experimentation. "Amelioration" includes alleviating undesirable symptoms, inducing a state of comfort or well-being, or eliminating or reducing biochemical, physiological, or clinical markers of a disease or disorder.

[0076] As used herein, the terms "treating," "treat," "treatment," or "improving" include administering an extract of the present disclosure or a composition comprising the extract in an effective amount sufficient to reduce or slow the onset or progression of a particular disorder, or to reduce or eliminate at least one symptom of the disorder. As understood by those skilled in the art of treating microbial infections, the term "treatment" includes curing the infection, but does not necessarily mean that the infection is completely cured.

[0077] As used herein, the term "preventing" or "prevent" includes administering an extract of the present disclosure or a composition comprising the extract in an effective amount sufficient to avoid the onset of a particular disorder or to avoid at least one symptom of the disorder. As understood by those skilled in the art of preventing disorders, the term "preventing" includes, but does not necessarily mean that the disorder is completely prevented.

[0078] As used herein, "subject" refers to an animal, such as a mammal, including a human, that can benefit from the sugarcane-derived extract, compositions containing the extract, and methods and uses described herein. There is no limitation on the type of animal that can benefit from the sugarcane-derived extract, compositions containing the extract, methods, and uses described herein. A subject, whether human or non-human, can be referred to as an individual, subject, animal, host or recipient, and patient. The materials of the present disclosure have applications in human medicine, human cosmetics, and veterinary medicine.

[0079] References to "compositions for" are understood to include the methods of the present disclosure.

[0080] As used herein, the term "about" means within a range of + / - 5% of a given value.

[0081] The term "CE" or "catechin equivalent" as used herein is a measure of total polyphenol content and is expressed as catechin equivalents per gram of material or catechin equivalents per gram of material.

[0082] As used herein, the term "sugarcane-derived products" refers to products of the sugarcane milling and refining process, including, but not limited to, sugar, molasses, mascuite, bagasse, first press, mill mud, clarified cane juice, clarified syrup, treacle, golden syrup, field waste, sugarcane strippings, leaves, crop chips, pulp and dunder, and combinations thereof. Dunder is the residue produced when products such as sugar and molasses are fermented to make ethanol. Sugarcane dunder is also known as biodunder, stillage, or vinasse. As used herein, the terms "dunder," "biodunder," "stillage," and "distillation residue" are equivalent and may be used interchangeably.

[0083] Throughout this specification, various aspects and components of the present disclosure may be expressed in a range format. The range format is included for convenience and should not be construed as an inflexible limitation on the scope of the present disclosure. Thus, unless otherwise indicated, the description of a range should be considered to have specifically disclosed all possible subranges and individual numerical values ​​within that range. For example, a description of a range such as 1 to 5 should be considered to have specifically disclosed subranges such as 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 5, 3 to 5, etc. Unless an integer is required or implied by context, individual numerical values ​​and partial numerical values ​​within a recited range are included, such as 1, 2, 3, 4, 5, 5.5, 6, etc. This applies regardless of the breadth of the range disclosed. If a specific value is required, the specification will state so.

[0084] Throughout this specification, word variations such as "comprise" or "comprises" or "comprises" are understood to imply the inclusion of an element, integer, step, or group of elements, integers, or steps, but not the exclusion of other elements, integers, steps, or group of elements, integers, or steps. In one embodiment, the sugarcane-derived extract of the present disclosure comprises at least about 10 CE / L of polyphenols or at least about 150 mg CE / g of polyphenols. As previously stated, the term "CE" or "catechin equivalent" is a measure of total polyphenol content and is expressed as mg catechin equivalents / g extract from sugarcane or g catechin equivalents / L extract from sugarcane.

[0085] In one embodiment, the sugarcane-derived extract of the present disclosure comprises at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 CE g / L of polyphenols.

[0086] In one embodiment, the sugarcane-derived extract of the present disclosure comprises at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 250, 275, 300, 325, 350, 375, 400, 425, 450, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775 or 800 mg CE / g polyphenols.

[0087] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 1 CE g / L to about 50 CE g / L of polyphenols or from about 10 CE mg / g to about 500 CE mg / g of polyphenols.

[0088] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 1 CE g / L to about 25 CE g / L of polyphenols or from about 10 CE mg / g to about 250 CE mg / g of polyphenols.

[0089] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 1 CE g / L to about 10 CE g / L of polyphenols or from about 10 CE mg / g to about 100 CE mg / g of polyphenols.

[0090] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 1 CE g / L to about 5 CE g / L of polyphenols or from about 10 CE mg / g to about 100 CE mg / g of polyphenols.

[0091] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 5 CE g / L to about 50 CE g / L of polyphenols or from about 50 CE mg / g to about 500 CE mg / g of polyphenols.

[0092] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 5 CE g / L to about 25 CE g / L of polyphenols or from about 50 CE mg / g to about 250 CE mg / g of polyphenols.

[0093] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 5 CE g / L to about 10 CE g / L of polyphenols or from about 50 CE mg / g to about 100 CE mg / g of polyphenols.

[0094] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 10 CE g / L to about 100 CE g / L of polyphenols or from about 100 CE mg / g to about 1000 CE mg / g of polyphenols.

[0095] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 10 CE g / L to about 90 CE g / L of polyphenols or from about 100 CE mg / g to about 900 CE mg / g of polyphenols.

[0096] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 10 CE g / L to about 80 CE g / L of polyphenols or from about 100 CE mg / g to about 800 CE mg / g of polyphenols.

[0097] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 10 CE g / L to about 70 CE g / L of polyphenols or from about 100 CE mg / g to about 700 CE mg / g of polyphenols.

[0098] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 10 CE g / L to about 60 CE g / L of polyphenols or from about 100 CE mg / g to about 600 CE mg / g of polyphenols.

[0099] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 10 CE g / L to about 50 CE g / L of polyphenols or from about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0100] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 10 CE g / L to about 25 CE g / L of polyphenols or from about 100 CE mg / g to about 250 CE mg / g of polyphenols.

[0101] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 15 CE g / L to about 50 CE g / L of polyphenols or from about 150 CE mg / g to about 500 CE mg / g of polyphenols.

[0102] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 15 CE g / L to about 25 CE g / L of polyphenols or from about 150 CE mg / g to about 250 CE mg / g of polyphenols.

[0103] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 10 CE g / L to about 70 CE g / L of polyphenols or from about 100 CE mg / g to about 700 CE mg / g of polyphenols.

[0104] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 10 CE g / L to about 60 CE g / L of polyphenols or from about 100 CE mg / g to about 600 CE mg / g of polyphenols.

[0105] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 10 CE g / L to about 50 CE g / L of polyphenols or from about 100 CE mg / g to about 500 CE mg / g of polyphenols.

[0106] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 15 CE g / L to about 40 CE g / L of polyphenols or from about 150 CE mg / g to about 400 CE mg / g of polyphenols.

[0107] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 20 CE g / L to about 30 CE g / L of polyphenols or from about 200 CE mg / g to about 300 CE mg / g of polyphenols.

[0108] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 20 CEg / L to about 27 CEg / L of polyphenols or from about 200 CE mg / g to about 270 CE mg / g of polyphenols.

[0109] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 27 CEg / L to about 35 CEg / L of polyphenols or from about 270 CE mg / g to about 350 CE mg / g of polyphenols.

[0110] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 35 CEg / L to about 40 CEg / L of polyphenols or from about 350 CE mg / g to about 400 CE mg / g of polyphenols.

[0111] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 40 CEg / L to about 50 CEg / L of polyphenols or from about 400 CE mg / g to about 500 CE mg / g of polyphenols.

[0112] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 45 CE g / L to about 50 CE / L of polyphenols or from about 450 CE mg / g to about 500 CE mg / g of polyphenols.

[0113] The sugarcane-derived extract of the present disclosure may contain polyphenols of the flavonoid class. The sugarcane-derived extract may contain any amount of flavonoids. In one embodiment, the sugarcane-derived extract of the present disclosure contains at least about 1 CE g / L of flavonoids or at least about 10 CE mg / g of flavonoids.

[0114] In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 1 CE g / L to about 15 CE g / L of flavonoids, or from about 10 CE mg / g to about 150 CE mg / g of flavonoids. In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 3 CE g / L to about 10 CE g / L of flavonoids, or from about 30 CE mg / g to about 100 CE mg / g of flavonoids. In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 5 CE g / L to about 8 CE g / L of flavonoids, or from about 50 CE mg / g to about 80 CE mg / g of flavonoids. In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 6 CE g / L to about 8 CE g / L of flavonoids, or from about 60 CE mg / g to about 80 CE mg / g of flavonoids. In one embodiment, the sugarcane-derived extract of the present disclosure comprises from about 6.5 CE g / L to about 7.5 CE g / L of flavonoids, or from about 65 CE mg / g to about 75 CE mg / g of flavonoids.

[0115] The sugarcane-derived extract of the present disclosure may contain proanthocyanidin polyphenols. The sugarcane-derived extract may contain any amount of proanthocyanidins. In one embodiment, the sugarcane-derived extract of the present disclosure contains at least about 1.5 CE g / L of proanthocyanidins, or at least about 15 CE mg / g of proanthocyanidins. In one embodiment, the sugarcane-derived extract of the present disclosure contains at least about 1.8 CE g / L of proanthocyanidins, or at least about 18 CE mg / g of proanthocyanidins. In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 1.5 CE g / L to about 2.5 CE g / L of proanthocyanidins, or from about 15 CE mg / g to about 25 CE mg / g of proanthocyanidins. In one embodiment, the sugarcane-derived extract of the present disclosure contains from about 1.8 CE g / L to about 2.2 CE g / L of proanthocyanidins or from about 18 CE mg / g to about 22 CE mg / g of proanthocyanidins.

[0116] The polyphenols of the sugarcane-derived extract of the present disclosure include, but are not limited to, one or more of syringic acid, chlorogenic acid, caffeic acid, vanillin, sinapic acid, p-coumaric acid, ferulic acid, gallic acid, vanillic acid, diosmin, diosmetin, apigenin, vitexin, orientin, homoorientin, swerticin, tricin, (+)-catechin, (-)-catechin gallate, (-)-epicatechin, quercetin, kaempferol, myricetin, rutin, schaftside, isoschaftside, luteolin, scoparin, and / or derivatives thereof. The polyphenols of the sugarcane-derived extract of the present disclosure include, but are not limited to, one or more of hydroxycinnamic acid, isoorientin, swerticiajaponin, neocarlinoside, isovitexin, vicenin, and / or derivatives thereof.

[0117] The polyphenols of the sugarcane-derived extract also include, for example, glycosides, glucosides, galactosides, galacturonides, ethers, esters, arabinosides, sulfates, phosphates, aldopentoses (xylose, arabinose) and aldohexoses.

[0118] In one embodiment, the sugarcane-derived extract of the present disclosure comprises syringic acid, chlorogenic acid, caffeic acid, vanillin, sinapic acid, diosmin, diosmetin, apigenin, vitexin, orientin, homoorientin, swerticin, and tricin and / or derivatives thereof.

[0119] In one embodiment, the sugarcane-derived extract of the present disclosure comprises syringic acid, chlorogenic acid, diosmin and / or derivatives thereof.

[0120] In one embodiment, the sugarcane-derived extract of the present disclosure comprises syringic acid. In one embodiment, the sugarcane-derived extract of the present disclosure comprises chlorogenic acid. In one embodiment, the sugarcane-derived extract of the present disclosure comprises diosmin. In one embodiment, the sugarcane-derived extract of the present disclosure comprises caffeic acid. In one embodiment, the sugarcane-derived extract of the present disclosure comprises vanillin. In one embodiment, the sugarcane-derived extract of the present disclosure comprises sinapic acid. In one embodiment, the sugarcane-derived extract of the present disclosure comprises vitexin. In one embodiment, the sugarcane-derived extract of the present disclosure comprises p-coumaric acid. In one embodiment, the sugarcane-derived extract of the present disclosure comprises ferulic acid. In one embodiment, the sugarcane-derived extract of the present disclosure comprises gallic acid. In one embodiment, the sugarcane-derived extract of the present disclosure comprises vanillic acid. In one embodiment, the sugarcane-derived extract of the present disclosure comprises diosmetin. In one embodiment, the sugarcane-derived extract of the present disclosure comprises apigenin. In one embodiment, the sugarcane-derived extract of the present disclosure comprises orientin. In one embodiment, the sugarcane-derived extract of the present disclosure comprises homoorientin. In one embodiment, the sugarcane-derived extract of the present disclosure comprises swerticin. In one embodiment, the sugarcane-derived extract of the present disclosure comprises tricin. In one embodiment, the sugarcane-derived extract of the present disclosure comprises (+)-catechin. In one embodiment, the sugarcane-derived extract of the present disclosure comprises (-)-catechin gallate. In one embodiment, the sugarcane-derived extract of the present disclosure comprises (-)-epicatechin. In one embodiment, the sugarcane-derived extract of the present disclosure comprises quercetin. In one embodiment, the sugarcane-derived extract of the present disclosure comprises kaempferol. In one embodiment, the sugarcane-derived extract of the present disclosure comprises myricetin. In one embodiment, the sugarcane-derived extract of the present disclosure comprises rutin. In one embodiment, the sugarcane-derived extract of the present disclosure comprises schaftside. In one embodiment, the sugarcane-derived extract of the present disclosure comprises isoschaftside. In one embodiment, the sugarcane-derived extract of the present disclosure comprises luteolin. In one embodiment, the sugarcane-derived extract of the present disclosure comprises scoparin. In one embodiment, the sugarcane-derived extract of the present disclosure comprises hydroxycinnamic acid.In one embodiment, the sugarcane-derived extract of the present disclosure comprises isoorientin. In one embodiment, the sugarcane-derived extract of the present disclosure comprises swartiajaponin. In one embodiment, the sugarcane-derived extract of the present disclosure comprises neocarlinoside. In one embodiment, the sugarcane-derived extract of the present disclosure comprises isovitexin. In one embodiment, the sugarcane-derived extract of the present disclosure comprises vicenin.

[0121] In one embodiment, the three most abundant polyphenols in the sugarcane-derived extract of the present disclosure are syringic acid, chlorogenic acid, and diosmin.

[0122] In one embodiment, the sugarcane-derived extract of the present disclosure contains about 5-20 μg / g dry weight of syringic acid. In one embodiment, the sugarcane-derived extract of the present disclosure contains about 7-15 μg / g dry weight of syringic acid. In one embodiment, the sugarcane-derived extract of the present disclosure contains about 10-12 μg / g dry weight of syringic acid. In one embodiment, the sugarcane-derived extract of the present disclosure contains about 10.9 μg / g dry weight of syringic acid, if present. The sugarcane-derived extract may be in the form of a syrup.

[0123] In one embodiment, the sugarcane-derived extract of the present disclosure contains about 50-200 μg / g dry weight of syringic acid. In one embodiment, the sugarcane-derived extract of the present disclosure contains about 90-130 μg / g dry weight of syringic acid. In one embodiment, the sugarcane-derived extract of the present disclosure contains about 100-120 μg / g dry weight of syringic acid. In one embodiment, the sugarcane-derived extract of the present disclosure contains about 107 μg / g dry weight of syringic acid. The sugarcane-derived extract may be in powder form.

[0124] In one embodiment, the sugarcane-derived extract of the present disclosure contains about 1-15 μg / g dry weight of chlorogenic acid. In one embodiment, the sugarcane-derived extract of the present disclosure contains about 3-10 μg / g dry weight of chlorogenic acid. In one embodiment, the sugarcane-derived extract of the present disclosure contains about 5-8 μg / g dry weight of chlorogenic acid. In one embodiment, the sugarcane-derived extract of the present disclosure contains about 6.53 μg / g dry weight of chlorogenic acid. The sugarcane-derived extract may be in the form of a syrup.

[0125] In one embodiment, the sugarcane-derived extract of the present disclosure contains about 30-150 μg / g dry weight of chlorogenic acid. In one embodiment, the sugarcane-derived extract of the present disclosure contains about 60-90 μg / g dry weight of chlorogenic acid. In one embodiment, the sugarcane-derived extract of the present disclosure contains about 70-80 μg / g dry weight of chlorogenic acid. In one embodiment, the sugarcane-derived extract of the present disclosure contains about 74 μg / g dry weight of chlorogenic acid. The sugarcane-derived extract may be in powder form.

[0126] In one embodiment, the sugarcane-derived extract of the present disclosure contains about 10-30 μg / g dry weight of diosmin. In one embodiment, the sugarcane-derived extract of the present disclosure contains about 15-25 μg / g dry weight of diosmin. In one embodiment, the sugarcane-derived extract of the present disclosure contains about 18-21 μg / g dry weight of diosmin. In one embodiment, the sugarcane-derived extract of the present disclosure contains about 19-45 μg / g dry weight of diosmin. The sugarcane-derived extract may be in the form of a syrup.

[0127] In one embodiment, the sugarcane-derived extract of the present disclosure contains about 100-300 μg / g dry weight of diosmin. In one embodiment, the sugarcane-derived extract of the present disclosure contains about 190-260 μg / g dry weight of diosmin. In one embodiment, the sugarcane-derived extract of the present disclosure contains about 210-240 μg / g dry weight of diosmin. In one embodiment, the sugarcane-derived extract of the present disclosure contains about 227 μg / g dry weight of diosmin. The sugarcane-derived extract may be in powder form.

[0128] In one embodiment, the sugarcane-derived extract of the present disclosure contains about 7-15 μg / g dry weight of syringic acid, and / or about 4-9 μg / g dry weight of chlorogenic acid, and / or about 0.1-0.5 μg / g dry weight of caffeic acid, about 0.05-0.3 μg / g dry weight of vanillin, and / or about 0.1-0.3 μg / g dry weight of sinapic acid, and / or about 15-25 μg / g dry weight of diosmin, and / or about 0.1-0.4 μg / g dry weight of orientin, and / or about 0.4-0.9 μg / g dry weight of swerticin, and / or about 0.05-0.3 μg / g dry weight of disomentin. The sugarcane-derived extract may be in the form of a syrup.

[0129] In one embodiment, the sugarcane-derived extract of the present disclosure contains about 10-12 μg / g dry weight of syringic acid, and / or about 5-8 μg / g dry weight of chlorogenic acid, and / or about 0.2-0.4 μg / g dry weight of caffeic acid, and / or about 0.1-0.2 μg / g dry weight of vanillin, and / or about 0.1-0.25 μg / g dry weight of sinapic acid, and / or about 18-21 μg / g dry weight of diosmin, and / or about 0.2-0.3 μg / g dry weight of orientin, and / or about 0.5-0.8 μg / g dry weight of swerticin, and / or about 0.1-0.2 μg / g dry weight of disomentin. The sugarcane-derived extract may be in the form of a syrup.

[0130] In one embodiment, the sugarcane-derived extract of the present disclosure contains about 10.9 μg / g dry weight of syringic acid, and / or about 6.53 μg / g dry weight of chlorogenic acid, and / or about 0.29 μg / g dry weight of caffeic acid, and / or about 0.153 μg / g dry weight of vanillin, and / or about 0.18 μg / g dry weight of sinapic acid, and / or about 19.45 μg / g dry weight of diosmin, and / or about 0.245 μg / g dry weight of orientin, and / or about 0.69 μg / g dry weight of swerticin, and / or about 0.15 μg / g dry weight of disomentin. The sugarcane-derived extract may be in the form of a syrup.

[0131] In one embodiment, the sugarcane-derived extract of the present disclosure contains about 90-130 μg / g dry weight of syringic acid, and / or about 60-90 μg / g dry weight of chlorogenic acid, and / or about 4-10 μg / g dry weight of caffeic acid, and / or about 1-4 μg / g dry weight of vanillin, about 1-3 μg / g dry weight of sinapic acid, and / or about 190-260 μg / g dry weight of diosmin, and / or about 3-7 μg / g dry weight of orientin, and / or 3-8 μg / g dry weight of swerticin, and / or about 0.05-0.3 μg / g dry weight of disomentin. The sugarcane-derived extract may be in powder form.

[0132] In one embodiment, the sugarcane-derived extract of the present disclosure contains about 100-120 μg / g dry weight of syringic acid, and / or about 70-80 μg / g dry weight of chlorogenic acid, and / or about 6-8 μg / g dry weight of caffeic acid, about 2-3 μg / g dry weight of vanillin, and / or about 1.5-2.5 μg / g dry weight of sinapic acid, and / or about 210-240 μg / g dry weight of diosmin, about 4-5 μg / g dry weight of orientin, 4-6 μg / g dry weight of swerticin, and / or about 0.1-0.2 μg / g dry weight of disomentin. The sugarcane-derived extract may be in powder form.

[0133] In one embodiment, the sugarcane-derived extract of the present disclosure contains about 107 μg / g dry weight of syringic acid, and / or about 74 μg / g dry weight of chlorogenic acid, and / or about 7.5 μg / g dry weight of caffeic acid, and / or about 2 μg / g dry weight of vanillin, and / or about 1.7 μg / g dry weight of sinapic acid, and / or about 227 μg / g dry weight of diosmin, and / or about 4.5 μg / g dry weight of orientin, 5.2 μg / g dry weight of swerticin, and / or about 0.16 μg / g dry weight of disomentin. The sugarcane-derived extract may be in powder form.

[0134] The sugarcane-derived extract of the present disclosure may contain a range of organic acids naturally found in sugarcane. These organic acids may include, but are not limited to, aconitic acid (cis- and trans-), oxalic acid, citric acid, lactic acid, tartaric acid, glycolic acid, succinic acid, citric acid, malic acid, fumaric acid, and shikimic acid. In one embodiment, the sugarcane-derived extract contains higher levels of citric acid and malic acid than other organic acids. In another embodiment, the sugarcane-derived extract contains small to trace amounts of oxalic acid, citric acid, tartaric acid, glycolic acid, succinic acid, and citric acid. In another embodiment, the two most abundant organic acids in the sugarcane-derived extract are trans- and cis-aconitic acid.

[0135] The sugarcane-derived extract of the present disclosure may contain trans- and / or cis-aconitic acid. In one embodiment, the sugarcane-derived extract of the present disclosure contains about 10,000-40,000 mg / kg of trans-aconitic acid and / or about 3,000-7,000 mg / kg of cis-aconitic acid. In one embodiment, the sugarcane-derived extract of the present disclosure contains about 17,000-30,000 mg / kg of trans-aconitic acid and / or about 4,000-6,500 mg / kg of cis-aconitic acid. In one embodiment, the sugarcane-derived extract of the present disclosure may contain about 20,000-25,000 mg / kg of trans-aconitic acid and / or about 5,000-5,500 mg / kg of cis-aconitic acid.

[0136] The sugarcane-derived extract of the present disclosure may contain amino acids. In one embodiment, the total amino acid level of the sugarcane-derived extract of the present disclosure is about 50,000-80,000 μg / g, about 60,000-70,000 μg / g, or about 65,000 μg / g. In one embodiment, about 10-40% of these total amino acids are essential amino acids. In one embodiment, about 15-30% of these total amino acids are essential amino acids. In one embodiment, about 20-25% of these total amino acids are essential amino acids.

[0137] The sugarcane-derived extract of the present disclosure may contain free amino acids. In one embodiment, the sugarcane-derived extract of the present disclosure contains about 10,000 to 50,000 μg of free amino acids per gram. In one embodiment, the sugarcane-derived extract of the present disclosure may contain about 20,000 to 35,000 μg of free amino acids per gram. The sugarcane-derived extract of the present disclosure may contain about 25,000 to 30,000 μg of free amino acids per gram.

[0138] As stated above, the term "free amino acid" as used herein means an amino acid that is a single molecule and is not structurally bound by peptide bonds to other amino acids.

[0139] The sugarcane-derived extract of the present disclosure may contain the branched essential amino acid leucine. In one embodiment, the concentration of leucine in the sugarcane-derived extract is about 1 to 5 mM, about 1.5 to 4 mM, or about 2 to 3 mM. In one embodiment, the amount of leucine in the sugarcane-derived extract is about 1,000 to 20,000 μg / g, about 1,000 to 10,000 μg / g, about 1,000 to 5,000 μg / g, about 1,000 to 2,000 μg / g, about 5,000 to 10,000 μg / g, or about 10,000 to 20,000 μg / g.

[0140] The sugarcane-derived extract of the present disclosure may contain minerals. In one embodiment, the sugarcane-derived extract contains minerals that are naturally present in sugarcane. In one embodiment, the sugarcane-derived extract contains one or more minerals, including, but not limited to, potassium, sodium, calcium, magnesium, iron, zinc, selenium, and chromium.

[0141] In one embodiment, the sugarcane-derived extract contains minerals bound to polyphenols. In one embodiment, the sugarcane-derived extract contains divalent ions bound to polyphenols. In one embodiment, the sugarcane-derived extract contains calcium, magnesium, and / or iron bound to polyphenols. In one embodiment, the sugarcane-derived extract contains iron bound to polyphenols.

[0142] In one embodiment, the sugarcane-derived extract of the present disclosure contains, per kg, about 20,000 to 32,000 mg of potassium, and / or about 300 to 600 mg of sodium, and / or about 800 to 1,300 mg of calcium, and / or about 3,000 to 6,000 mg of magnesium, and / or about 40 to 90 mg of iron, and / or about 3 to 10 mg of zinc, and / or about 500 to 900 μg of selenium, and / or about 1,000 to 1,600 μg of chromium. The sugarcane-derived extract may be in the form of a syrup.

[0143] In one embodiment, the sugarcane-derived extract of the present disclosure contains, per kg, about 25,000-27,000 mg of potassium, and / or about 400-500 mg of sodium, and / or about 1,000-1,200 mg of calcium, and / or about 4,000-5,500 mg of magnesium, and / or about 55-75 mg of iron, and / or about 5.5-7.5 mg of zinc, and / or about 700-850 μg of selenium, and / or about 1,200-1,400 μg of chromium. The sugarcane-derived extract may be in the form of a syrup.

[0144] In one embodiment, the extract of the present disclosure derived from sugarcane of the present disclosure contains per kg about 26,000 mg potassium, and / or about 450 mg sodium, and / or about 1,090 mg calcium, and / or about 4,700 mg magnesium, and / or about 65 mg iron, about 6.6 mg zinc, and / or about 786 μg selenium, and / or about 1,300 μg chromium. The extract derived from sugarcane may be in the form of a syrup.

[0145] In one embodiment, the sugarcane-derived extract of the present disclosure contains, per kg, about 50 to 350 mg of potassium, and / or about 5 to 70 mg of sodium, and / or about 7,000 to 10,000 mg of calcium, and / or about 1,000 to 3,000 mg of magnesium, and / or about 500 to 1,300 mg of iron. The sugarcane-derived extract may be in powder form.

[0146] In one embodiment, the sugarcane-derived extract of the present disclosure contains, per kg, about 100 to 250 mg of potassium, and / or about 10 to 50 mg of sodium, and / or about 8,000 to 9,000 mg of calcium, and / or about 1,500 to 2,500 mg of magnesium, and / or about 800 to 1,000 mg of iron. The sugarcane-derived extract may be in powder form.

[0147] In one embodiment, the extract of the present disclosure derived from sugarcane of the present disclosure contains about 190 mg potassium, and / or about 30 mg sodium, and / or about 8,800 mg calcium, and / or about 2,000 mg magnesium, and / or about 890 mg iron per kg. The extract derived from sugarcane may be in powder form.

[0148] The sugarcane-derived extracts of the present disclosure may contain monosaccharides, disaccharides, oligosaccharides, and / or polysaccharides, examples of which include, but are not limited to, sucrose, glucose, galactose, xylose, ribose, mannose, rhamnose, fructose, maltose, lactose, maltotriose, xylopyranose, raffinose, 1-kestose, theanderose, 6-kestose, panose, neokestose, nystose, glucan, and xylan.

[0149] In one embodiment, the compositions and methods include about 0.00001% to about 10% by weight of the extract.

[0150] In one embodiment, the compositions and methods include from about 0.00001% to about 50% by weight of the extract.

[0151] In one embodiment, the compositions and methods include from about 0.00001% to about 50% by weight of the extract.

[0152] In one embodiment, the compositions and methods include about 5% to about 10% by weight of the extract.

[0153] In one embodiment, the compositions and methods include about 0.05% to about 10% by weight of the extract.

[0154] In one embodiment, the compositions and methods include about 0.05% to about 5% by weight of the extract.

[0155] In one embodiment, the virus is a coronavirus.

[0156] In one embodiment, the virus is an influenza virus, including H1N1, swine flu, and avian flu.

[0157] In one embodiment, the virus is SARS-CoV-2.

[0158] In one embodiment, the virus is a flavivirus, including dengue virus, Zika virus, West Nile virus, and yellow fever virus.

[0159] In one embodiment, the virus is Hendra virus.

[0160] In one embodiment, the disease is caused by a protozoan such as malaria, dysentery, giardia, cryptosporidium, chaga disease, or coccidiosis.

[0161] In one embodiment, agricultural greenhouse gas emissions are caused by methanogens, which are archaeal bacteria.

[0162] In one embodiment, the disease is caused by a microsporidia such as Enterocytozoon hepatopenae.

[0163] In one embodiment, the composition for inhibiting and / or treating a viral infection is a topical cleanser, preferably a hand wash.

[0164] In one embodiment, the composition for inhibiting and / or treating a viral infection is an oral formulation, preferably a mouthwash, gargle or ingestible liquid, or a solid such as a tablet, capsule, lozenge or confectionery. Capsules are particularly preferred.

[0165] In one embodiment, the composition for oral administration may be contained in a liquid, solid, or semi-solid food product.

[0166] In one embodiment, the composition may be included in a non-human animal feed.

[0167] In one embodiment, the composition for inhibiting and / or treating a viral infection is an aerosol for pulmonary administration.

[0168] In one embodiment, the composition for inhibiting and / or treating a viral infection is a nasal spray or is formulated for intranasal administration.

[0169] In one embodiment, the composition for inhibiting and / or treating a viral infection is formulated for administration by a nebulizer.

[0170] In one embodiment, the composition for inhibiting and / or treating a viral infection is formulated for intravenous administration.

[0171] In one embodiment, the composition for inhibiting and / or treating a viral infection is formulated for pulmonary administration.

[0172] In one embodiment, the composition for inhibiting and / or treating a viral infection is formulated for buccal or sublingual administration.

[0173] In one embodiment, the composition for inhibiting and / or treating a viral infection is formulated for transdermal administration.

[0174] The preparation of the sugarcane-derived extracts of the present disclosure is broadly described in International Publication No. WO 2019 / 028506, in particular at pages 17 to 40, line 22 of which the preparation of these extracts is described, which is incorporated herein by cross-reference.

[0175] Similarly, WO 2019 / 028506, which is incorporated herein by cross-reference, describes the composition of a sugarcane-derived extract on page 50, line 16 to page 51, line 24. WO 2019 / 028506 also describes the characteristics of a sugarcane extract on pages 64 to 88, line 9.

[0176] More generally, the disclosure of International Publication No. WO2019 / 028506 is incorporated herein by cross-reference.

[0177] Detailed analysis of the sugarcane-derived extract samples of the present disclosure revealed the following components: Chlorogenic acid 2423ng / mL Vanillic acid 16088ng / mL Caffeic acid 482ng / ml Trans-caffeic acid 273ng / ml p-Coumaric acid 14445ng / ml Other compounds that contain luteolin, trans-resveratrol, diosmetin, swerticin, and rutin are flavonoids, apigenin-6-C-arabinosyl-8-C glucoside, apigenin-6-C-glucosyl-8-C arabinoside, apigenin-6,8-C-diglucoside, apigenin-6"-O-glucosyl-8-C glucoside, schaftosid-2"-O-glucoside, apigenin-6-C-rhamnosyl-8-C glucoside, apigenin-6,8-C-diarabinoside, methoxyluteolin-8-C-glucoside, methoxyluteolin-6"-O-rutinosyl-8-C-glucoside, methoxyluteolin-6"-O-glucosyl-8-C-glucoside, and tricin. It was found to exist together with 7-O-neohesperidoside, tricin 7-O-rhamnosyl-glucuronide and tricin 7-O-glycoside.

[0178] The formulation of the extract into a composition of the present disclosure suitable for human use can be prepared by any method known in the art of formulation. Exemplary techniques for formulating the composition of the present disclosure are described in "Remington's Pharmaceutical Sciences", Mack Publishing Co., Easton Pa., 22nd Edition, 2012.

[0179] In one embodiment, the extracts of the present disclosure may be spray-dried and incorporated directly into capsules for human consumption. Typically, such compositions do not require additional carriers, although carriers such as lactose may be used. In this type of product, each capsule may contain 10-1000 mg. Capsules containing 100-500 mg of spray-dried material are preferred, with 250 mg or 500 mg capsules being particularly preferred.

[0180] In one embodiment, the extracts of the present disclosure can be spray-dried and formulated into sublingual tablets for ingestion into the human buccal cavity. This type of product can contain 10-1000 mg per tablet. Tablets containing 100-500 mg of spray-dried material are preferred, with tablets containing 250 mg of spray-dried material or 500 mg of spray-dried material being particularly preferred.

[0181] In one embodiment, the extracts of the present disclosure can be formulated into a liquid or semisolid, such as a syrup or gel, for sublingual ingestion into the buccal cavity of a human. In this type of product, the liquid or gel can contain 10-30% w / w of the extract. Preferred concentrations are 15-20% w / w or 20-30% w / w.

[0182] Spray drying of the extracts of the present disclosure may be carried out by known methods, which may or may not include a carrier such as maltodextrin.

[0183] In one embodiment, the extract can be spray dried at 100% concentration using a spray dryer with an inlet temperature of 140-150°C and an outlet temperature of 90-95°C.

[0184] In one embodiment, the extract may be spray dried at 80% concentration using maltodextrin carrier, with the inlet temperature of the spray dryer being 150-160°C and the outlet temperature being 90-95°C.

[0185] In one embodiment, the extracts of the present disclosure may be formulated into a spray for human nasal or oral administration. In this type of product, the spray may contain 0.01-10% w / v, 0.01-5.0% w / v, 0.1-2.0% w / v, or 1.0-2.5% w / v.

[0186] Compositions applicable to non-human animals are extensively described, for example, in International Publication No. WO 2019 / 028506, e.g., at

[0238] to

[0251] and

[0253] to

[0254] , the contents of which are incorporated herein by cross-reference.

[0187] In one embodiment, the extract of the present disclosure may be incorporated into feed at a concentration of 0.001% to 10% w / w or w / v in the case of liquid feed, in a composition applicable to non-human animals.

[0188] In one embodiment, the extract of the present disclosure may be incorporated into feed at a concentration of 0.01% to 5% w / w or w / v in the case of liquid feed in a composition applicable to non-human animals.

[0189] In one embodiment, the extract of the present disclosure may be incorporated into feed at a concentration of 0.1% to 2% w / w or w / v in the case of liquid feed in a composition applicable to non-human animals.

[0190] In one embodiment, the extract of the present disclosure may be incorporated into feed at a concentration of 0.001% to 10% w / w, preferably 0.01% to 5%, and most preferably 0.1% to 2% or % w / v for liquid feeds to achieve a methane reduction of 3 to 80% in compositions suitable for ruminants.

[0191] In one embodiment, the extracts of the present disclosure may be incorporated into feed at a concentration of 0.001% to 10% w / w, preferably 0.01% to 5%, and most preferably 0.1% to 2% or w / v for liquid feeds to achieve a methane reduction of 5 to 70% in compositions suitable for ruminants.

[0192] In one embodiment, the extracts of the present disclosure may be incorporated into feed at a concentration of 0.001% to 10% w / w, preferably 0.01% to 5%, and most preferably 0.1% to 2% or w / v in liquid feed to achieve a methane reduction of 10 to 60% in compositions suitable for ruminants.

[0193] In one embodiment, the extracts of the present disclosure may be incorporated into feed at a concentration of 0.001% to 10% w / w, preferably 0.01% to 5%, and most preferably 0.1% to 2% or w / v for liquid feeds to achieve a methane reduction of 5 to 50% in compositions suitable for ruminants.

[0194] In one embodiment, the extracts of the present disclosure may be incorporated into feed at a concentration of 0.001% to 10% w / w, preferably 0.01% to 5%, and most preferably 0.1% to 2% or w / v for liquid feeds to achieve a methane reduction of 5 to 40% in compositions suitable for ruminants.

[0195] In one embodiment, the extracts of the present disclosure may be incorporated into feed at a concentration of 0.001% to 10% w / w, preferably 0.01% to 5%, and most preferably 0.1% to 2% or w / v in liquid feed to achieve a methane reduction of 10 to 30% in compositions suitable for ruminants.

[0196] In one embodiment, the extracts of the present disclosure may be incorporated into feed at a concentration of 0.001% to 10% w / w, preferably 0.01% to 5%, and most preferably 0.1% to 2% or w / v in liquid feed to achieve a methane reduction of 5-10% in compositions suitable for ruminants.

[0197] In one embodiment, the extract of the present disclosure may be incorporated into feed at a concentration of 0.001% to 10% w / w, preferably 0.01% to 5%, and most preferably 0.1% to 2% or w / v in liquid feed to achieve an increase in milk production of 1 to 15%, or 2 to 10%, or 3 to 7% in compositions suitable for ruminants.

[0198] In one embodiment, the extracts of the present disclosure may be incorporated into the aquatic environment at a concentration of 0.1-2.0% v / v in a composition suitable for non-human aquatic animals such as shrimp and prawns.

[0199] In one embodiment, the extracts of the present disclosure may be incorporated into the aquatic environment at a concentration of 0.1-1.0% v / v in a composition suitable for non-human aquatic animals such as shrimp and prawns.

[0200] In one embodiment, the extracts of the present disclosure may be incorporated into the aquatic environment at a concentration of 0.1-0.6% v / v in a composition suitable for non-human aquatic animals such as shrimp and prawns.

[0201] In one embodiment, the extract of the present disclosure may be incorporated into the aquatic environment at a concentration of 0.3-0.6% v / v in a composition suitable for non-human aquatic animals such as shrimp and prawns.

[0202] Example 1 of the preparation of an extract of the present disclosure is described below. This extract was named Polygaine. The stillage is stored in a recyclable tank before use. The stillage feed was passed through a 10 μm mesh to remove large particles. The ingredients were then mixed at high shear. After mixing, the mixture was heated to 55°C. The heated material was filtered through a 0.1 μm membrane filtration system. After filtration, it was evaporated to 60 brix. When stored as a liquid, it was heated to 80°C and packaged. If spray dried material was required, the 60 brix product was blended with maltodextrin and mixed thoroughly. The slurry thus formed was spray dried at an inlet temperature of 150-160°C and an outlet temperature of 90-95°C.

[0203] [Table 1] The polyphenol content of Polygain was measured as follows.

[0204] Example 2 of the preparation of an extract of the present disclosure is described below. This extract was named Bilophonol. 1. 300 kg of sugarcane extract was mixed with 900 L of hot water (80 to 85°C). 2. Mix thoroughly and ensure the brix is ​​20 before adding to a settling tank filled with FPX-66 resin. 3. After mixing for 20 minutes, the resin was allowed to settle for 15-20 minutes. 4. It was passed through a 200 μm prefilter into the tank. 5. The excess liquid was drained and discarded. 6. The resin was washed off with approximately 1000 L of cold water, mixed well and drained. 7. Ethanol was added to the settling tank along with the resin at 71-76%. 8. After mixing for 20 minutes, the resin was allowed to settle for 15-20 minutes. 9. The liquid was collected by passing it through a 200 μM prefilter into a tank. 10. Steps 7 to 9 were repeated. 11. After all the liquid was collected, 500 L of warm water (35-40°) was added to the resin. 12. After mixing for 20 minutes, the product was allowed to stand for 15-20 minutes. 13. The fluid was drained and collected. 14. All collected liquid was added to an evaporator and concentrated to 45 Brix. 15. A liquid of 45Brix with an inlet temperature ranging from 140-150°C and an outlet temperature ranging from 90-95°C was spray dried, sieved and packaged.

[0205] Next, further embodiments of the present disclosure, such as Example 3, will be described.

[0206] Test Protocol Four solutions were evaluated to determine whether any solution could directly inactivate SARS-CoV-2 disease. Of these, Solution 4 is the composition of the present disclosure, and water is used as a negative control.

[0207] Protocol 1To 50 μL of each solution, 50 μL of SARS-CoV-2 stock (undiluted) was added. After 1 minute (simulating time spent in the oral cavity), 500 μL of infection medium was added to "quench" the disinfection reaction. Samples were then directly plated onto TCID50 plates as quickly as possible (n=4 / dilution). The percentage of wells that were CPE-positive was recorded compared to the positive control sample.

[0208] 100µL of SARS-CoV-2 stock was exposed to equal volumes (100µL) of pure and diluted solutions. After 1 minute, the virus:substrate solution was serially diluted and TCID50 was determined. The change in TCID50 / mL was compared to a positive control sample.

[0209] 50% Tissue Culture Infectious Dose Assay (TCID50): In the PC2 laboratory, plates were inoculated to establish a monolayer of approximately 95% Vero cells 24 hours prior to the assay. After verifying the monolayer mass / density, the plates were washed using infection medium (to remove cellular debris) and transferred to the PC3 laboratory. Samples were generated, serially diluted, and a known volume was inoculated into each well. n=4 replicates per sample. The plates were incubated to allow for viral infection of the monolayer, after which MEM infection medium (containing penicillin / streptomycin, glutamine, and HEPES, but no FBS) + TPCK trypsin (1 μg / mL) was added. The plates were returned to the incubator (37°C, 5% CO2) and microscopically inspected for cytopathic effect (CPE) on the cells every 24 hours (up to 72 hours). The TCID50 / mL of infectious virus present in the original sample was then determined using the Reed-Muench 1938 method, "A Simple Method for Estimating the 50th Percentage Endpoint," American Journal of Hygiene, Vol. 3.

[0210] resultSolution 4 showed fully effective virucidal activity when directly exposed to SARS-CoV-2. For both the quench and TCID50 assays, no virus-induced CPE was detectable when Solution 4 was used undiluted. On the other hand, Solutions 1 and 2 showed no obvious virucidal activity. Solution 3 showed obvious virucidal activity. The results are shown in Figure 1.

[0211] In further Example 4, compositions of the present disclosure were evaluated in a SARS-CoV-2 virus yield reduction assay. Using SARS-CoV-2 patient isolate (Australia / VIC01 / 2020) virus, composition samples were resuspended at 10 mg / mL in infection medium (MEM+Abx+HEPES, serum-free). Samples were tested at concentrations of 10 μg / mL, 5 μg / mL, 2.5 μg / mL, 1.25 μg / mL, and 0.625 μg / mL (final concentrations after virus addition: 5, 2.5, 1.25, 0.625, and 0.313 μg / mL).

[0212] Testing protocol: One day before the start of the experiment, Vero cells were seeded into 24-well plates. The next day, the cells were infected with 100 μL of 100 TCID50 and incubated at 37°C for 1 hour. °C New stock (TCID50 / mL = 10 5.59 ) was used. In this experiment, 943±233 TCID was obtained by reflux titration in a 100uL inoculum. 50 obtained. Compounds were resuspended in DMSO at 10 mM (from the original 10 mg / mL stock) before diluting them in infection medium to the dose ranges described above and used the same day. After 1 hour of incubation with the virus, antiviral compounds were added to 100 L of SF medium, and 1 hour later, 0.8 ml of infection medium containing 1.2 g / ml trypsin (total volume in the well = 1 ml) was added. Immediately after adding the medium, 125 μL was sampled for the t=0 titer. 125 uL was replaced to maintain the volume in the well at 1 mL. At 24 and 48 hours post-infection, aliquots of supernatant were collected and TCID50 was performed to assess infectious virus titer.

[0213] 50% Tissue Culture Infectious Dose Assay (TCID 50 ) In the PC2 laboratory, 24 hours before the assay, plates were seeded to form approximately 95% monolayers of Vero cells. After verifying the monolayer mass / density, the plates were washed using infection medium (to remove cellular debris) and transported to the PC3 laboratory. Samples were generated and serially diluted, and a known volume was inoculated into each well. n=4 replicates / sample. Incubate the plates at 4°C to allow viral infection of the monolayer, after which MEM infection medium (containing penicillin / streptomycin, glutamine, HEPES, but no FBS) + TPCK trypsin (1 ug / mL) is added. Place the plate in an incubator (37°C). o C, 5% CO2) and examined microscopically for cytopathic effect (CPE) every 24 hours (up to 72 hours). °C. Then, the TCID of infectious virus present in the original sample 50 / mL was measured by the Reed-Muench method.

[0214] Results: Log TCIDTCID 24 h post-infection 50 / mL value: [Table 2]

[0215] [Table 3] Results: TCID 48 h after infection 50 / mL value:

[0216] In a further example 5, Vero cells were infected with West Nile virus for 2 hours and then treated with different concentrations of the compositions of the present disclosure.

[0217] FIG. 2 shows the results of Example 5.

[0218] In further Example 6, six species of coccidia were cultured in 1980 L of RPMI medium. These were isolates of the sporozoite life stage. These species included E. maxima, E. acervulina, E. burnetii, E. tenella, E. necatrix, and E. mitis. They were then treated with 20 L of a composition of the present disclosure.

[0219] The results are shown in Figure 3.

[0220] In further Example 7, a coccidial challenge study was conducted using Ross 308 male boiler chickens. One-day-old chickens were assigned to experimental groups containing different concentrations of the disclosed composition in their diet, or the antibiotic ionophore salinomycin in their diet, or a control group with no additives in their diet. On day 14, the birds were administered a 20-fold dose of a live vaccine formulation containing three Eimeria strains: E. maxima, E. acervulina, and E. tenella. Seven days after Eimeria challenge, birds from each treatment group were euthanized, and a qualified veterinarian scored the lesions in their gastrointestinal tract caused by coccidial infection.

[0221] The results are shown in Figure 4.

[0222] In further Example 8, the fecal microbiota of eight thoroughbred horses was sequenced over a five-day period to determine the baseline microbial community present. 100 ml of the composition of the present disclosure was administered every 24 hours for 28 days. Gene sequencing of fecal samples was then repeated for five days. The administration of the extract was then discontinued. After another 28 days, the fecal microbiota of the eight horses was again sequenced.

[0223] The results are shown in Figure 5.

[0224] In further Example 9, the production of infectious influenza A virus (IAV) progeny in vitro (after additional exposure of cells to virus) was evaluated in the presence of a range of concentrations of a composition of the present disclosure (referred to in this example as "virofol"), and infectious virus titers were measured using a quantitative assay.

[0225] Influenza A virus (IAV) (A / Beijing 89 strain, a representative seasonal strain of the H3N2 subtype) was used. The final concentrations of the composition of the present disclosure (virofonol) added 1 hour after virus infection were 10, 5, and 2.5 μg / mL. Virus recovery was assessed at 2 and 24 hours post-infection (hpi). The 2-hour time point was used to assess residual input virus, and the 24-hour time point was used to assess infectious virus after replication and virus production.

[0226] The infection protocol used was as follows: MDCK cells were seeded into 12-well plates one day before the start of the experiment, with one well reserved for cell counting before infection. The next day, cells were washed twice with infection medium and counted. Cells were infected at an MOI of 1.0 in 150 μL and incubated at 37°C for 1 hour, with gentle shaking of the plate every 10 minutes. Compounds were resuspended in infection medium at a concentration of 10 mg / ml and filtered through a 0.22 μm syringe filter. The compound is diluted in infection medium to 10, 5 and 2.5 μg / mL. After 1 h of incubation, the inoculum was removed and all wells were washed twice with infection medium. The diluted antiviral compounds were immediately added at a volume of 1 mL per well. At 2 and 24 hours post-infection (hpi), the supernatants were collected and centrifuged at 13,000 rpm for 5 minutes in a microcentrifuge (ie, the cell-free supernatant containing the virus was collected). The clarified supernatant was stored at -80°C in two aliquots. Plaque assays were performed to assess infectious virus titers.

[0227] The plaque assay used was as follows. 2xL15 medium was placed in a 45°C water bath. To ensure cleavage of IAV HA, virus samples were preactivated with 4 μg / ml trypsin Worthington. Ten-fold serial dilutions of virus samples were performed in cold serum-free RPMI+. The medium was aspirated from a confluent 6-well plate of MDCK cells and replaced with 2 ml of serum-free RPMI+. The RPMI+ was aspirated and 150 μL of virus dilution was added to two wells. The plate was then placed at 37°C / 5% CO2 for 1 hour to allow virus infection. The agarose was heated in a microwave oven until completely melted and then placed in a 45°C water bath. An agarose overlay (3 ml total) consisting of L15 medium containing 0.9% (w / v) agarose and 2 μg / ml trypsin Worthington was added. After the coating layer solidified, the cells were returned to a 37°C / 5% CO2 incubator for 3 days to allow viral plaque formation. The plates were held up to the light and the plaques were counted.

[0228] The results obtained are as follows (Table 1).

[0229] Table 1 [Table 4]

[0230] When added postinfection, virofol exhibited antiviral effects against representative seasonal IAV strains, revealing its intracellular mechanism of action. No significant changes were observed at 2 hpi, which was an assessment of input virus before replication was established. The greatest antiviral effect was observed when virofol was added at concentrations greater than 5 μg / mL at 1 h postinfection, and analysis was performed at 24 h postinfection. This indicates that virofol exerts antiviral activity against IAV at a specific stage of the viral life cycle after virus entry and replication.

[0231] In further Example 10, we evaluated the production of infectious ZIKV virion progeny in the presence of a range of concentrations of virilonol added during and after in vitro infection. The TCID50 assay was used as a quantitative measure of infectious virus titer because it provides more technical replicates with fewer samples and all assays can be performed in the same plate, ensuring greater consistency.

[0232] Influenza A virus (IAV) (A / Beijing 89 strain, a representative seasonal strain of the H3N2 subtype) was used. Final concentrations during and after virus addition were 10, 5, and 2.5 μg / mL. Virus recovery was 2-24 hours post-infection (hpi).

[0233] The infection protocol used was as follows: MDCK cells were seeded into 12-well plates one day before the start of the experiment, leaving one well for cell counting before infection. The next day, the cells were washed twice with infection medium and counted. Compounds were resuspended in infection medium at a concentration of 10 mg / ml and filtered through a 0.22 μm syringe filter. Compounds were diluted in infection medium to 10, 5 and 2.5 μg / mL. Virus was incubated with diluted compounds at each concentration in infection medium at MOI=1.0 in 150 uL / well at 37° C. for 1 hour. Cells were infected with compound-incubated virus for 1 hour. The inoculum was removed. All wells were washed twice with infection medium. The corresponding diluted antiviral compounds were added again in a volume of 1 mL per well. Supernatants were collected at 2 and 24 hpi and centrifuged at 13,000 rpm for 5 min in a microcentrifuge (cell-free supernatant was collected). The clarified supernatant was stored at -80°C in two aliquots. TCID50 assay was performed to assess infectious virus titer.

[0234] The TCID50 protocol used was as follows: MDCK cells were seeded into 96-well plates one day before the experiment, with eight wells per virus dilution, one plate per sample. The next day, cells were washed twice with infection medium. Trypsin Worthington was added to the infection medium at a final concentration of 2 ug / ml. To ensure cleavage of IAV HA, virus samples were preactivated with 4 μg / ml trypsin Worthington. The virus was diluted 1:10 in infection medium and 100 μl of each dilution was transferred to six wells: column 7 was a positive control (virus of known titer) and column 8 was a negative control. The cells were incubated at 37°C in 5% CO2 for 3 days and monitored daily. Estimated PFU / ml was calculated by standard conversion from TCID50.

[0235] The results obtained are as follows (Table 2). Table 2 [Table 5]

[0236] When incubated with virus as a pre- and post-infection treatment, virofol was found to exhibit antiviral activity against representative seasonal IAV strains. These findings suggest a potential direct viricidal effect of virofol on the virus and a cellular mechanism of action for this compound. No significant changes were observed at 2 hpi, which was an assessment of input virus before replication was established. When virus titers were quantified at 24 hpi, virofol concentrations of 5 μg / mL or higher were found to have the greatest effect.

[0237] In further Example 11, we evaluated the production of infectious ZIKV virion progeny in the presence of a range of concentrations of virilonol added during and after in vitro infection. The TCID50 assay was used as a quantitative measure of infectious virus titer. This allows for more technical replicates with fewer samples, and all assays can be performed in the same plate, ensuring greater consistency. Asian Zika virus (ZIKV) was used, with final concentrations of 10, 5, and 2.5 μg / mL during and after virus addition. Time points were 24 and 48 h postinfection (hpi).

[0238] The infection protocol used was as follows: Vero cells were seeded into 12-well plates one day before the start of the experiment, reserving one well for cell counting before infection. The next day, cells were washed twice with warm PBS and counted. Compounds were resuspended in infection medium at a concentration of 10 mg / ml and filtered through a 0.22 μm syringe filter. Compounds were diluted in infection medium to 10, 5 and 2.5 μg / mL. The virus was incubated with diluted compounds at each concentration in infection medium at 300 uL / well, MOI=1.0, 37° C. for 1 hour. Cells were infected with compound-incubated virus for 1 hour. The inoculum was removed and all wells were washed twice with warm PBS. The corresponding diluted antiviral compounds were added again in a volume of 1 mL per well. Supernatants were collected at 24 and 48 hpi and centrifuged at 13,000 rpm for 5 min in a microcentrifuge. The clarified supernatant was stored at -80°C in two aliquots. TCID50 assay was performed to assess infectious virus titer.

[0239] The TCID50 protocol used was as follows: Vero vesicles were seeded into 96-well plates one day before the experiment. Eight wells were prepared for each virus dilution. One plate was prepared for each sample. The next day, cells were washed twice with warm PBS. The virus was diluted 1:10 in infection medium (serum reduced) and 100 μl of each dilution was transferred to six wells: column 7 was a positive control (virus of known titer) and column 8 was a negative control. Incubated in 5% CO2 at 37°C for 5 days and monitored daily. The estimated PFU / ml was calculated from TCID50.

[0240] The results obtained are as follows (Table 3).

[0241] Table 3 [Table 6]

[0242] When incubated with virus as a preinfection treatment and maintained in cell culture during the assay, virofol demonstrated antiviral effects against ZIKV Asian. These findings suggest the possibility of virofol exerting an extracellular virucidal effect (direct antiviral effect on the virus) and an intracellular mechanism of action (acting on the cells) by this compound. No significant changes were observed at 24 hpi, which was assessed with input virus before replication was fully established at 48 hpi. The greatest effect was observed with 50 μg / mL virofol after 48 hpi. This suggests that virofol affects the virus particle itself (viral effect) and / or its ability to infect and replicate within cells (cellular effect). Because the ZIKV replication cycle is longer than that of IAV, IAV was evaluated at 2 and 24 hpi, compared to 24 and 48 hpi for ZIKV.

[0243] Overall, Examples 9-11 demonstrate that virofol exhibited antiviral activity when applied directly to the viral inoculum itself and after the infection process for both IAV and ZIKV. These results demonstrate that virofol is useful as both an extracellular and intracellular antiviral agent.

[0244] In a further Example 12, the dose response of two compositions of the present disclosure (called Polynol and Polygaine) against (infectious laryngotracheitis virus) ILTVCSW1 was evaluated.

[0245] In this example, chicken (Leghorn) liver hepatoma cell line (LMH cells) was seeded in 12-well plates until 90% confluent. 1 x 10 cells in 400 μl 6 The cells were infected with pfu / mL of ILTV CSW1 virus for 1 hour. After 1 hour, various concentrations (Polynol: 0.5, 1, and 1.5 mg / ml; Polygaine: 1, 1.5, and 2 mg / ml) were added to the corresponding wells. The cells were incubated for 48 hours. After incubation, the cell culture medium was collected for plaque assay.

[0246] The results of this example are as follows (Table 4): Table 4 [Table 7]

[0247] In a further Example 13, the ability of a composition of the present disclosure (Polygain) to reduce methane emissions from dry cows was evaluated.

[0248] Dry cows were fed either 3 kg of concentrate mixture (control) or concentrate mixed with 100 g of Polygain. Methane concentrations were measured at 11:00 am and again at 1:00 pm.

[0249] The results in Figure 7 clearly show that Polygain significantly reduced methane emissions compared to the control group in the first two hours. These results demonstrate the microbial incompatibility effect of the composition of the present disclosure.

[0250] In a further Example 14, a composition of the present disclosure (Polygain) was evaluated for its ability to reduce methane production in vitro. In this example, rumen fluid samples were obtained and used to ferment samples of typical feedlot forage or Rhodosgrass. The samples under evaluation contained a 15% concentration of Polygain in each fermentation.

[0251] The results shown below show that for feedlot diets, methane production per gram of digested dry matter was reduced by 54% after 24 hours. For roadgrass diets, the reduction per gram of digested dry matter after 24 hours was 16.5%. [Table 8]

[0252] In a further Example 15, a composition of the present disclosure (Polygain) was evaluated for its ability to inhibit EHP polar tube extrusion activity.

[0253] The results shown in Figure 6 clearly demonstrate that Polygaine is highly effective in inhibiting EHP, as compared with PBS as a control. Therefore, it is clear that Polygaine plays a role in preventing EHP infection in shrimp and other aquatic species susceptible to EHP.

[0254] In a further Example 16, the ability of a composition of the present disclosure (Polygain) to increase milk production in dairy cows was evaluated. In this example, cows were fed a regular diet (control) or a regular diet containing 0.5% or 1.0% Polygain. Milk volume and concentrate were measured daily and the results are shown in Table 5.

[0255] Table 5 [Table 9]

[0256] These results show that cows supplemented with Polygain had an increase in milk production per cow of 2.1 L / day by day 7. This continued on day 41, when cows supplemented with Polygain had an increase in milk production of 1.8 L / day per cow. These represent increases of 6.3% and 5.8%, respectively.

[0257] Protein and fat content was maintained in all cows supplemented with Polygain.

[0258] Finally, to increase milk production, dairy cows supplemented with Polygaine require lower levels of concentrate.

[0259] In a further example 17, the composition of the present disclosure (Polygain) was evaluated for its ability to promote growth in calves. In this study, calves were fed a regular diet (control) or a regular diet containing 10 g of Polygain.

[0260] The diet consisted of 4.0 kg wheat, 1.0 kg corn, 1.0 kg canola meal, 0.1 kg limestone, 0.1 kg salt, 0.05 kg dicalcium phosphate, 0.04 kg magnesium oxide, and a vitamin and trace mineral premix, which was fed in the form of a granular or loose grain mixture.

[0261] The results of the experiment are shown in Table 6. They show that the mean total weight gain was 67.6 kg for the control group, compared to 70.5 kg for the test diet containing Polygain. The mean daily weight gain for the control group was 0.82 kg compared to 0.86 kg. This corresponds to a difference of 4.9%, which is very important in terms of the economic value of each animal.

[0262] In conjunction with the examples relating to the reduction of methane production, it is clear that the disclosed sugar extract provides a dual benefit: it reduces methane production while increasing body weight.

[0263] Table 6: [Table 10-1] Table 6 continued [Table 10-2] Table 6 continued [Table 10-3] Table 6 continued [Table 10-4] Table 6 continued [Table 10-5] Table 6 continued [Table 10-6]

[0264] In a further Example 18, the ability of a composition of the present disclosure (Polygain) to improve the health of dairy cows by preventing and / or treating mastitis was evaluated. Conductivity data was collected from over 4,000 milking sessions from 27 cows over a four-month period, divided into a control group and a group whose diet contained 1% w / w Polygain on a total dry matter basis.

[0265] As mentioned above, milk conductivity directly indicates the presence of mastitis in dairy cows. Generally, conductivity increases with the incidence of mastitis. It is rare for all four quarters (teaches) of a dairy cow to be infected. Therefore, the quarter with the lowest conductivity is compared to the other quarters as a ratio to indicate the presence of mastitis in one or more quarters. This measurement is usually collected automatically by so-called robotic milking equipment. Of course, milk samples can also be collected manually and the conductivity evaluated quarter by quarter.

[0266] In this Example 18, samples were collected within the robotic milking equipment. As shown in Table 7, not only did the average base conductivity decrease over time, but the average ratio between quarters also decreased. This strongly suggests that the improvement in dairy cow mammary gland health may be due to the prevention, treatment, and / or reduction in the incidence of mastitis.

[0267] Table 7 [Table 11]

[0268] In a further Example 19, a composition of the present disclosure (Polygain) was evaluated for its ability to reduce methane emissions from dry cows. Polygain was included in the diet of dairy cows in each test group at 0.5% or 1% w / w on a dry matter basis.

[0269] At the start of the study, methane concentrations were collected periodically over approximately 42 hours. After 32 days of feeding, methane concentrations were again collected periodically over approximately 42 hours.

[0270] The experimental results for 0.5% Polygain are shown in Figure 8, and the results for 1% Polygain are shown in Figure 9. Referring to Figure 8, qualitatively, it was found that the methane concentration in the 0.5% test group recorded four values ​​slightly above 0.2. Compared to the start, many values ​​above 0.2 were recorded.

[0271] 9, it was found that the methane concentration in the 1% test group did not exceed 0.2 qualitatively. Compared to the start of the experiment, many values ​​exceeding 0.2 were recorded.

[0272] Thus, this Example 19 clearly demonstrates the microbial incompatibility effect of the composition of the present disclosure.

[0273] In a further Example 20, feces from a dairy cow fed a control diet and a second dairy cow fed the same diet supplemented with 100 g of Polygain were evaluated for methanogenic archaeal populations.

[0274] The results of Example 20 are shown in Figure 10. These results suggest that the microbial populations were reduced by approximately 15% for Methanobacteriaceae Methanobrevibacter and approximately 30% for Methanosphaera. These results reinforce the findings in further examples disclosed herein that the methane reduction effect of Polygain is due to changes induced in the ruminant microbiota, specifically the population of methane-producing microorganisms.

[0275] It will be appreciated by those skilled in the art that many changes and / or modifications may be made to the above-described embodiments without departing from the broad general scope of the present disclosure, and the present embodiments are therefore considered in all respects to be illustrative and not restrictive.

Claims

1. 1. A method for reducing greenhouse gas emissions by an animal by altering the composition of a microbial community associated with the animal, comprising administering to the animal an effective amount of a composition comprising about 0.00001% to about 100% by weight of a sugar cane-derived extract, the extract comprising about 10 catechin equivalent (CE) g / L to about 100 CE g / L of polyphenols or about 100 CE mg / g to about 1000 CE mg / g of polyphenols and about 1 catechin equivalent (CE) g / L to about 15 CE g / L of flavonoids or about 10 CE mg / g to about 150 CE mg / g of flavonoids.

2. The method of claim 1 , wherein the animal is a ruminant and the microbial community is in the rumen.

3. The method of claim 1, wherein the extract comprises from about 10 catechin equivalents (CE) g / L to about 80 CE g / L of polyphenols and from about 1 CE g / L to about 15 CE g / L of flavonoids, or from about 100 CE mg / g to about 800 CE mg / g of polyphenols and from about 10 CE mg / g to about 150 CE mg / g of flavonoids.

4. The method of claim 3, wherein the extract contains about 10 CE g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.

5. A method according to any one of claims 1 to 4, wherein the composition is a feed containing about 0.001% by weight to about 10% by weight or 0.001% by weight / volume to about 10% by weight / volume of the extract.

6. The method described in claim 5, wherein the composition is a feed containing about 0.01% by weight to about 5% by weight or 0.01% by weight to about 5% by weight of the extract.

7. The method described in claim 6, wherein the composition is a feed containing about 0.1% by weight to about 2% by weight or 0.1% by weight / volume to about 2% by weight / volume of the extract.

8. A method according to any one of claims 5 to 7, wherein methane production by animals is reduced by 3 to 80%.

9. The method of claim 8, wherein methane production by animals is reduced by 5 to 70%.

10. 1. Use of about 0.00001% to about 100% by weight of an extract derived from sugar cane used in the preparation of a composition for reducing greenhouse gas emissions by an animal by altering the composition of the microbial community associated with the animal, the extract comprising about 10 catechin equivalent (CE) g / L to about 100 CE g / L of polyphenols or about 100 CE mg / g to 1000 CE mg / g of polyphenols and about 1 catechin equivalent (CE) g / L to about 15 CE g / L of flavonoids or about 10 CE mg / g to about 150 CE mg / g of flavonoids.

11. The use described in claim 10, wherein the animal is a ruminant and the microbial population is in the rumen.

12. The use of claim 10, wherein the extract comprises from about 10 catechin equivalents (CE) g / L to about 80 CE g / L polyphenols and from about 1 CE g / L to about 15 CE g / L flavonoids, or from about 100 CE mg / g to about 800 CE mg / g polyphenols and from about 10 CE mg / g to about 150 CE mg / g flavonoids.

13. The use of claim 12, wherein the extract contains about 10 CE g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.

14. The use described in any one of claims 10 to 13, wherein the composition is a feed comprising about 0.001% by weight to about 10% by weight or 0.001% by weight to about 10% by weight of the extract.

15. The use described in claim 14, wherein the composition is a feed containing about 0.01% by weight to about 5% by weight or 0.01% by weight to about 5% by weight of the extract.

16. The use described in claim 15, wherein the composition is a feed containing about 0.1% by weight to about 2% by weight or 0.1% w / v to about 2% w / v of the extract.

17. The use described in any one of claims 14 to 16, wherein methane production by animals is reduced by 3 to 80%.

18. The use of claim 17, wherein methane production by animals is reduced by 5 to 70%.